Post by Eli Lilly and Company

"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos." — Ania Jastreboff, M.D., Ph.D., Yale School of Medicine, lead investigator on the TRIUMPH-1 and TRANSCEND-T2D-1 trials. Across both Phase 3 studies, our investigational triple hormone receptor agonist delivered substantial weight loss alongside meaningful improvements in A1C, knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea severity for adults living with obesity — a breadth and magnitude of outcomes that is striking to see with a single therapy in clinical trials. Full results presented today at the #ADA2026 Scientific Sessions; TRANSCEND-T2D-1 simultaneously published in The Lancet Group. Read more: https://lnkd.in/eDiiTQ4q #ADA2026